US 12138276

Here's a concise summary of US Patent 12138276, including litigation status:

US Patent 12138276B2 Summary

• Title: Halogenated psilocybin derivatives and methods of using
• Assignee: Enveric Biosciences Canada Inc
• Inventors: Jillian M. Hagel, Peter J. Facchini
• Filing Date: 2024-05-06
• Issue Date: 2024-11-12
• Abstract: The patent describes halogenated psilocybin derivative compounds and methods for their synthesis and application. These compounds are intended for use in pharmaceutical and recreational drug formulations, including the treatment of psychiatric disorders. The disclosure also covers methods of manufacturing these derivatives.

Plain-Language Overview of Independent Claims:

• Claim 1: This claim covers a specific chemical compound (or its salts) that is a modified form of psilocybin. The modification involves replacing at least one hydrogen atom at positions R2, R4, R5, R6, or R7 on the core structure with a halogen atom (fluorine, chlorine, bromine, or iodine). Any other positions (R2, R5, R6, R7) not occupied by a halogen are hydrogen, an alkyl group, or an O-alkyl group. The R4 position, if not a halogen, can specifically be a phosphate group, hydrogen, an alkyl group, or an O-alkyl group. The R3A and R3B positions can be hydrogen, an alkyl, aryl, or acyl group.
• Claim 22: This claim is for a pharmaceutical or recreational drug formulation. It must contain an effective amount of a chemical compound as described in Claim 1 (the halogenated psilocybin derivative) along with a pharmaceutically acceptable excipient, diluent, or carrier.
• Claim 23: This claim describes a method for treating a psychiatric disorder. The method involves administering an effective amount of the pharmaceutical formulation from Claim 22 (containing a halogenated psilocybin derivative) to a subject who needs such treatment.
• Claim 26: This claim outlines a method for creating a halogenated psilocybin derivative. It involves taking a host cell that already contains enzymes necessary for psilocybin biosynthesis and exposing it to a pre-halogenated psilocybin precursor compound, which then leads to the production of the halogenated psilocybin derivative.
• Claim 35: This claim also describes a method for making a halogenated psilocybin derivative. In this method, a host cell with psilocybin biosynthetic enzymes is contacted with a non-halogenated psilocybin precursor compound and a halogen. Crucially, this host cell must also contain a halogenase enzyme, which is capable of introducing the halogen onto the non-halogenated precursor, thereby producing the halogenated psilocybin derivative.
• Claim 44: This claim is directed to a method for modulating (activating or inhibiting) the 5-HT2A receptor. The method involves exposing a 5-HT2A receptor to a chemical compound as defined in Claim 1 (the halogenated psilocybin derivative) under conditions suitable for altering the receptor's activity.
• Claim 47: This claim describes the use of a chemical compound as defined in Claim 1 (the halogenated psilocybin derivative) in the manufacturing process of a pharmaceutical or recreational drug formulation.
• Claim 50: This claim covers the use of a chemical compound as defined in Claim 1 (the halogenated psilocybin derivative), combined with a diluent, carrier, or excipient, specifically as a pharmaceutical or recreational drug formulation.

Litigation Status:

US Patent 12138276B2 is noted as having "Family has litigation" with a "First worldwide family litigation filed".

Specifically, a PTAB (Patent Trial and Appeal Board) case, PGR2025-00076, was filed and has reached a "Procedural Termination". This is a proceeding within the USPTO.

As of April 26, 2026, no direct docket entries or scheduled cases for US Patent 12138276B2 were found in the 2026 dockets of the U.S. Court of Appeals for the Federal Circuit (CAFC).